Tulane University Engages Bioscience Bridge for Selected Technology Transfer Representation

Share Article

Bioscience Bridge, LLC has announced its engagement by Tulane University as exclusive technology licensing agency for selected major life science patents and related intellectual property in cancer and neurology drug development.

“Flexibility of arrangements is a hallmark of our industry collaborations here at Tulane.”

Bioscience Bridge, LLC has announced its engagement by Tulane University as exclusive technology licensing agency for selected major life science patents and related intellectual property in cancer and neurology drug development.

The Office of Technology Transfer and Intellectual Property Development at Tulane will work directly with Bioscience Bridge principal, Michelle Travis.

The first two technologies to be represented by Bioscience Bridge are:

  •     Novel Ceramide Analogs with Added Amide Functional Group: AFG-added Ceramide Analogs (AFG-CAs) as Treatment for Breast Cancer
  •     Novel, Fast-Acting “Spontaneous” Cell-Penetrating Peptides (S-CPPs) for Intracellular Drug Delivery

Regarding the first technology, Travis says, “Current breast cancer management includes chemotherapy followed by endocrine therapies with selective estrogen receptor modulators (SERMs, such as tamoxifen) or estrogen ablation by aromatase inhibitors (such as anastrazole) or GnRH agonists (goserelin). However, resistance to chemotherapy and endocrine therapy remains a major cause of treatment failure. Evidence suggests that abnormal ceramide levels play a role, which has led to the development of a class of ceramide analogs as potential reversal agents. We present a novel approach to ceramide analogs that incorporate a new amide functional group developed by Tulane researchers working in collaboration with researchers at Xavier University in New Orleans, in the sphingosine backbone to affect the antiproliferative activity in breast cancer cells. These are unique AFG-added Ceramide Analogs (AFG-CAs).”

With more details on the second technology, Travis adds, “The blood-brain barrier and other lipid bilayers are obstacles to penetration of hydrophilic macromolecules, including peptides used as therapeutic agents. A class of Cell-Penetrating Peptides (CPPs) has emerged as a major opportunity for improving intracellular drug delivery. We present a novel approach developed by Tulane researchers for overcoming low biomembrane permeability and allowing intracellular delivery of therapeutic macromolecules – fast-acting “Spontaneous” Cell-Penetrating Peptides (or S-CPPs).”

John Christie, executive director of the Office of Technology Transfer and Intellectual Property Development at Tulane, comments, “As a licensing veteran, I appreciate the approach of Bioscience Bridge, and I look forward to their helping us expand the reach of our intellectual property representation among potential licensees and provide more opportunities for sponsored research.”

Christie adds that Tulane offers a wide range of options for interaction with industry, including research, device and materials testing, assistance with hiring, mentorship, or student internships. “Flexibility of arrangements is a hallmark of our industry collaborations here at Tulane,” he says. “Tulane has a talented faculty, highly qualified and motivated students, equipment, facilities and an experienced technology transfer office. Last year, our faculty worked on more than 700 projects sponsored by government agencies, private foundations and industry. We look forward to expanding the range of companies we work with and the number of Tulane technologies in active development.”

To learn more about these life science technologies, contact Michelle Travis, managing director at Michelle@biosciencebridge.com or 208-319-3624.

About Tulane University:
Founded in 1834, Tulane is one of the most highly regarded and selective independent research universities in the United States. It is proud to be a member of the prestigious Association of American Universities, a select group of 63 universities with “pre-eminent programs of graduate and professional education and scholarly research.” Tulane’s schools and colleges offer undergraduate, graduate and professional degrees in the liberal arts, science and engineering, architecture, business, law, social work, medicine and public health and tropical medicine.

About Tulane University’s Office of Technology Transfer and Intellectual Property Development:
Tulane offers a responsive, professional staff and a long history of success based on the discoveries and innovations of our faculty. The office currently manages 29 active licenses with 25 different companies. It has issued 94 patents based on the discoveries of its faculty since 1991. Tulane consistently ranks among the top 35 institutions in the US in annual royalty revenue, at present representing approximately 5% of its total sponsored research budget. The Office of Technology Transfer and Intellectual Property Development can assist with licensing of Tulane’s intellectual property; development of confidentiality agreements, material transfer agreements, and cooperative research and development agreements; and patent, trademark and copyright processes on behalf of Tulane.

About Bioscience Bridge, LLC:
Bioscience Bridge, LLC is a global technology transfer agency. We accelerate the connections of university-based bioscience research with commercial development opportunities. We are unique because we support tech transfer offices with our bioscience industry experience and a proven process in the evaluation, strategy, promotion and negotiation of licensing, collaboration or start up arrangements. The agency is a member of Association of Technology Managers (AUTM) and the Licensing Executives Society (LES). More information is on the Bioscience Bridge website at http://www.biosciencebridge.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Travis
Visit website